Identification

Name
Cetirizine
Accession Number
DB00341  (APRD00630)
Type
Small Molecule
Groups
Approved
Description

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem]

Structure
Thumb
Synonyms
  • Cetirizin
  • Cetirizina
  • Cetirizine
  • Cetirizinum
Product Ingredients
IngredientUNIICASInChI Key
Cetirizine hydrochloride64O047KTOA83881-52-1PGLIUCLTXOYQMV-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CetirizineTablet20 mgOralPro Doc Limitee2016-06-13Not applicableCanada
Reactine 20mg TabletTablet20 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc2002-01-14Not applicableCanada
Rhinaris ReliefTablet20 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
ZyrtecTablet, film coated5 mg/1OralPfizer Laboratories Div Pfizer Inc.1995-12-082010-12-08Us
ZyrtecTablet, chewable5 mg/1OralPfizer Laboratories Div Pfizer Inc.2004-03-162010-12-08Us
ZyrtecTablet, film coated10 mg/1Oralbryant ranch prepack2008-10-01Not applicableUs
ZyrtecTablet, film coated10 mg/1OralPfizer Laboratories Div Pfizer Inc.1995-12-082010-12-08Us
ZyrtecTablet, chewable5 mg/1OralPhysicians Total Care, Inc.2007-03-302007-12-30Us
ZyrtecTablet, chewable10 mg/1OralPfizer Laboratories Div Pfizer Inc.2004-03-162010-12-08Us
ZyrtecSyrup1 mg/1mLOralPfizer Laboratories Div Pfizer Inc.1996-09-272009-01-01Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cetirizineTablet20 mgOralApotex Corporation2016-04-22Not applicableCanada
Cetirizine HydrochlorideSyrup1 mg/1mLOralTeva2008-05-302015-11-30Us
Cetirizine HydrochlorideSyrup1 mg/1mLOralQualitest2009-09-252014-12-31Us
Cetirizine HydrochlorideSyrup1 mg/1mLOralPreferreed Pharmaceuticals Inc.2010-12-202017-12-28Us
Cetirizine hydrochlorideSolution1 mg/1mLOralPreferreed Pharmaceuticals Inc.2015-04-20Not applicableUs
Cetirizine hydrochlorideSolution1 mg/1mLOralHeritage2016-09-022020-03-31Us
Cetirizine HydrochlorideSolution1 mg/1mLOralPerrigo New York Inc2008-07-24Not applicableUs
Cetirizine HydrochlorideSyrup1 mg/1mLOralCaraco Pharmaceutical Laboratories, Ltd.2009-11-16Not applicableUs
Cetirizine HydrochlorideSyrup1 mg/1mLOralCypress Pharmaceuticals, Inc.2008-10-062013-09-11Us
Cetirizine HydrochlorideTablet10 mg/1OralDirectrx2016-12-22Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour AllergyTablet, film coated10 mg/1OralMeijer Distribution1997-07-07Not applicableUs
24 Hour AllergyLiquid5 mg/5mLOralMeijer Distribution2008-04-162017-07-13Us
24 Hour AllergyCapsule10 mg/1OralWalgreens2018-09-14Not applicableUs
24 Hour AllergyCapsule10 mg/1OralWalgreens2013-03-01Not applicableUs
24 Hour Allergy Lil Drug Store ProductsTablet10 mg/1OralLil' Drug Store Products, Inc.2014-11-01Not applicableUs
24-Hour All Day AllergyTablet10 mg/1OralMc Kesson2012-04-27Not applicableUs
7 Select All Day AllergyTablet10 mg/1Oral7 Eleven2014-04-29Not applicableUs
7 Select Childrens Allergy ReliefSolution5 mg/5mLOral7 Eleven2014-08-05Not applicableUs
All Day AllergyLiquid5 mg/5mLOralKroger2008-05-082017-08-02Us
All Day AllergyCapsule10 mg/1OralHyvee2013-09-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
12 Hour Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralMeijer Distribution1988-07-15Not applicableUs
All Day Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralKroger Company2014-02-19Not applicableUs
All day Allergy dCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralMajor2008-05-06Not applicableUs
All Day Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralHyvee2008-05-05Not applicableUs
all day Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralH E B2008-05-02Not applicableUs
All Day Allergy-DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralL. Perrigo Company2011-09-06Not applicableUs
Allergy and Congestion Relief D Original Prescription StrengthCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralRite Aid Corporation2008-04-10Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralCVS Health2008-04-10Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralPublix Super Markets Inc2010-03-11Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralH.E.B.2018-01-19Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ZyrtecCetirizine hydrochloride (5 mg/1)TabletOralPhysicians Total Care, Inc.2002-12-162009-01-18Us
ZyrtecCetirizine hydrochloride (10 mg/1)TabletOralPhysicians Total Care, Inc.1996-12-182009-01-18Us
International/Other Brands
Alerlisin / Cetryn / Formistin / Hitrizin / Virlix / Zirtek / Zyrlex
Categories
UNII
YO7261ME24
CAS number
83881-51-0
Weight
Average: 388.888
Monoisotopic: 388.155370383
Chemical Formula
C21H25ClN2O3
InChI Key
ZKLPARSLTMPFCP-UHFFFAOYSA-N
InChI
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
IUPAC Name
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
SMILES
OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria

Associated Conditions
Pharmacodynamics

Cetirizine, the active metabolite of the piperazine H1-receptor antagonist hydroxyzine, is used to treat chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis.

Mechanism of action

Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine

Volume of distribution
Not Available
Protein binding

Very high (93%) plasma protein binding

Metabolism
Not Available
Route of elimination
Not Available
Half life

8.3 hours

Clearance
  • 53 mL/min [healthy]
Toxicity

Somnolence (sleepiness or unusual drowsiness), restlessness, irritability

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cetirizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1,10-PhenanthrolineThe therapeutic efficacy of Cetirizine can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Cetirizine.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Cetirizine.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Cetirizine.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Cetirizine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with 7-Nitroindazole.
AbexinostatThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Acebutolol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Manne Reddy, "Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof." U.S. Patent US20040186112, issued September 23, 2004.

US20040186112
General References
Not Available
External Links
Human Metabolome Database
HMDB0005032
KEGG Compound
C07778
PubChem Compound
2678
PubChem Substance
46508368
ChemSpider
2577
BindingDB
22890
ChEBI
3561
ChEMBL
CHEMBL1000
Therapeutic Targets Database
DAP000323
PharmGKB
PA448905
IUPHAR
1222
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cetirizine
ATC Codes
R06AE07 — Cetirizine
AHFS Codes
  • 04:08.00 — Second Generation Antihistamines
FDA label
Download (54.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceChronic Prostatitis With Chronic Pelvic Pain Syndrome1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
1CompletedBasic ScienceAllergies1
1CompletedPreventionSkin Inflammation1
1CompletedTreatmentHealthy Volunteers3
1TerminatedBasic ScienceMigraines1
1, 2CompletedTreatmentNeuromyelitis Optica1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Seasonal1
2CompletedTreatmentAllergic / Rhinitis / Rhinitis, Allergic, Seasonal / Seasonal1
2CompletedTreatmentRhinitis, Allergic, Seasonal1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)3
3CompletedNot AvailableAllergic Rhinitis (AR)2
3CompletedTreatmentDermatitis, Eczematous / Skin Inflammation1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentRhinitis, Allergic, Perennial1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
4CompletedNot AvailableAllergic Rhinitis (AR)1
4CompletedNot AvailableAllergies2
4CompletedNot AvailablePerennial Allergic Rhinitis (PAR) / Seasonal Allergic Rhinitis (SAR)3
4CompletedDiagnosticAsthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR) / Pollen Allergy / Rhinitis, Allergic, Seasonal / Severe Acute Respiratory Syndrome1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4CompletedTreatmentRhinitis, Allergic, Perennial and Seasonal1
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentUrticarias2
4Enrolling by InvitationTreatmentDiabetic Neuropathy, Painful / Pain, Neuropathic / Type 2 Diabetes Mellitus1
4RecruitingBasic ScienceExercise Intolerance at Altitude1
4RecruitingTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4TerminatedTreatmentPruritus1
4TerminatedTreatmentUrticarias1
4Unknown StatusTreatmentSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableCognition / Driving Ability / Seasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableSeasonal Allergic Rhinitis (SAR) / Sinusitis1
Not AvailableCompletedTreatmentActinic Keratosis (AK)1
Not AvailableCompletedTreatmentSeasonal Allergic Rhinitis (SAR)1

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Actavis mid atlantic llc
  • Amneal pharmaceuticals
  • Apotex inc
  • Aurobindo pharma ltd
  • Cypress pharmaceutical inc
  • Dr reddys laboratories ltd
  • Perrigo israel pharmaceuticals ltd
  • Ranbaxy laboratories ltd
  • Sun pharmaceutical industries inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • Wockhardt ltd
  • Perrigo r and d co
  • Mcneil consumer healthcare div mcneil ppc inc
  • Caraco pharmaceutical laboratories ltd
  • Sandoz inc
  • Pfizer inc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Cadista pharmaceuticals inc
  • Contract pharmacal corp
  • Mylan pharmaceuticals inc
  • Orchid healthcare
  • Torrent pharmaceuticals llc
  • Unichem laboratories ltd
  • Unique pharmaceutical laboratories
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Apotex Inc.
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • CVS Pharmacy
  • Cypress Pharmaceutical Inc.
  • Direct Dispensing Inc.
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • EZ-EM Inc.
  • H.J. Harkins Co. Inc.
  • J.B. Chemicals & Pharmaceuticals
  • Kaiser Foundation Hospital
  • L Perrigo Co.
  • Lake Erie Medical and Surgical Supply
  • McNeil Laboratories
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pfizer Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • US Pharmaceutical Group
  • Vangard Labs Inc.
  • Warner Chilcott Co. Inc.
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
SyrupOral1 mg/1
TabletOral10.0 mg/1
Tablet, film coated, extended releaseOral
Capsule, liquid filledOral10 mg/1
SolutionOral1 mg/1mL
SyrupOral1 mg/1mL
SyrupOral5 mg/5mL
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
LiquidOral5 mg/5mL
SolutionOral5 mg/5mL
Tablet, orally disintegratingOral10 mg/1
SyrupOral5 mg
TabletOral10 mg
TabletOral5 mg
TabletOral20 mg
CapsuleOral10 mg
Tablet, chewableOral10 mg
Tablet, chewableOral5 mg
Tablet, extended releaseOral
Tablet, orally disintegratingOral10 mg
Tablet, chewableOral10 mg/1
Tablet, chewableOral5 mg/1
Tablet, multilayer, extended releaseOral
Prices
Unit descriptionCostUnit
Cetirizine HCl 100 10 mg tablet Bottle259.71USD bottle
Cetirizine HCl 100 5 mg tablet Bottle259.71USD bottle
Zyrtec 10 mg tablet2.66USD tablet
Zyrtec 5 mg tablet2.66USD tablet
Zyrtec itchy eye 0.025% drops2.62USD ml
Cetirizine hcl 5 mg chew tablet2.5USD tablet
Cetirizine hcl 10 mg tablet2.49USD tablet
Cetirizine hcl 5 mg tablet2.49USD tablet
Zyrtec-d tablet1.33USD tablet
Child's zyrtec chew tablet0.9USD tablet
CVS Pharmacy allergy relief 10 mg tablet0.74USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6469009No2002-10-222019-07-13Us
US7226614No2007-06-052022-06-10Us
US6489329No2002-12-032016-04-08Us
US7014867No2006-03-212022-06-10Us
US6455533No2002-09-242018-07-02Us
US9254286Yes2016-02-092033-01-09Us
US8829005Yes2014-09-092030-09-15Us
US9750684No2017-09-052030-03-15Us
US9993471No2010-03-152030-03-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)112.5 °CPhysProp
water solubility101 mg/LNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0658 mg/mLALOGPS
logP2.98ALOGPS
logP0.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.6ChemAxon
pKa (Strongest Basic)7.79ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.87 m3·mol-1ChemAxon
Polarizability41.88 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6863
Blood Brain Barrier+0.7576
Caco-2 permeable-0.5879
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.7364
P-glycoprotein inhibitor IINon-inhibitor0.7624
Renal organic cation transporterNon-inhibitor0.5232
CYP450 2C9 substrateNon-substrate0.8408
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.8885
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9465
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6917
Ames testNon AMES toxic0.7815
CarcinogenicityNon-carcinogens0.9426
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.6841 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.866
hERG inhibition (predictor II)Inhibitor0.6517
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000j-0900000000-9801bb859e79fa9922aa
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-014b559d56b0f32984ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-213bd47e17d5ab69ad4b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004r-9006000000-f496e22c8e0e293fe98c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-d8a55ab1a7aff0580a91
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-d8a55ab1a7aff0580a91
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-dc957bb6f947575ae4fa
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000b-0900000000-48fc0581ff9fff15e16d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-04ca95fadd952d0aaeb8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-014b559d56b0f32984ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0009000000-26a7769df28c2325ec53
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0009000000-284c2e7b25733d7c9875
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0009000000-04befed283d691217ba2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-14715ff4d57580fbb166
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0069000000-431df9c3533b77cf08bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-e042b67e2048318e7dbd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-b0dfb67717c01fd0c0b9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0970000000-e2810b242fefb4a419e7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-72f7cddc4ff6d45f98c0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-d6044767562f707c8061
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0059000000-15be2621a731a6c2b0ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-01f33b4e54bcb6c8720c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-f28111ea9c76c1bd27dd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0970000000-673301f54b883df73a2a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-81ab05c275bd28fa3dfb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-82d8eb507c79b7342917
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-0f667566feb3af808386
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0690000000-0d4336539c5ebe9050c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-1638816057d01db5eaa1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-de2feb9a65604f442606
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-58d302681ca058e5706c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0391000000-7af5014f07bed862bba6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0491000000-ac48bba9129fe5016c4b

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Diphenylmethane / Chlorobenzene / Halobenzene / N-alkylpiperazine / Aralkylamine / Aryl halide / 1,4-diazinane / Aryl chloride / Piperazine / Amino acid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, ether, monochlorobenzenes, piperazines (CHEBI:3561)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Christophe B, Carlier B, Gillard M, Chatelain P, Peck M, Massingham R: Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. Eur J Pharmacol. 2003 May 30;470(1-2):87-94. [PubMed:12787835]
  3. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093]
  4. Tillement JP, Testa B, Bree F: Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003 Oct 1;66(7):1123-6. [PubMed:14505791]
  5. Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. [PubMed:10597865]
  6. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]

Drug created on June 13, 2005 07:24 / Updated on December 16, 2018 06:37